Purple Biotech Ltd. (PPBT)

NASDAQ: PPBT · IEX Real-Time Price · USD
2.62
-0.06 (-2.24%)
At close: Aug 11, 2022 4:00 PM
2.65
+0.03 (1.15%)
After-hours: Aug 11, 2022 7:56 PM EDT
-2.24%
Market Cap 49.58M
Revenue (ttm) n/a
Net Income (ttm) 19.04M
Shares Out 18.92M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,417
Open 2.65
Previous Close 2.68
Day's Range 2.58 - 2.69
52-Week Range 2.10 - 5.18
Beta 1.95
Analysts n/a
Price Target n/a
Earnings Date n/a

About PPBT

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and sign... [Read more...]

Industry Biotechnology
Founded 2010
CEO Itzhak Israel
Employees 19
Stock Exchange NASDAQ
Ticker Symbol PPBT
Full Company Profile

Financial Performance

Financial Statements

News

Purple Biotech Reports Second Quarter 2022 Financial Results

REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable...

Purple Biotech Announces Executive Leadership Changes

Gil Efron appointed as Chief Executive Officer

Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & E...

A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer

Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients

Decision based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC) Decision based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC)

Purple Biotech Reports First Quarter 2022 Financial Results

REHOVOT, Israel, May 12, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable ...

Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Resear...

First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC

Purple Biotech Reports Second Half and Full-Year 2021 Financial Results

REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable...

Purple Biotech Issues Letter to Shareholders

REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durab...

Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors

REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable...

Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer

REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable...

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of M...

Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX ® ), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Cancer or Colorectal Adenoca...

Purple Biotech to Present at the Jefferies London Healthcare Conference

REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durab...

Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequen...

Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable...

Purple Biotech to Present at the Jefferies Virtual Healthcare Conference

REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable ...

Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting

Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors

REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durabl...

Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients

Preliminary Data from First Part of Study Anticipated in Second Half of 2021

Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021...

TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur...

Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers

Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb

Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 20...

TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur...

Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors

Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies by ov...

PPBT Stock: 9 Things for Investors to Know About Purple Biotech as Shares Surge

Purple Biotech (PPBT) stock is heading higher on Wednesday with heavy trading of the shares despite a lack of news about the company. The post PPBT Stock: 9 Things for Investors to Know About Purple Bio...

Purple Biotech to Present at the B. Riley Oncology Investor Conference

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio...